The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
There is a recent growing evidence that abnormalities in the microbiota composition can have a major role in the development of obesity and diabetes and that some actions of metformin may be mediated by gut bacteria. Several mechanisms have been found. A reduced microbial diversity is associated to inflammation, insulin-resistance, and adiposity. In particular, a rise in the Firmicutes/Bacteroidetes ratio is related to a low-grade inflammation and to an increased capability of harvesting energy from food. Interestingly, high-fat-diet favors the growth of bacteria capable of extracting more energy from food. Changes in some metabolites, such as short-chain fatty acids (SCFAs), produced by gut microbiota, and decreased amounts of the Akkermansia muciniphila are associated with the presence of type 2 diabetes. Among the mechanisms by which metformin acts on glucose metabolism and on the cardiovascular risk, some of them are due to positive effects on gut microbiota. A shift toward positive SCFAs produced by bacteria, an increase in some bacterial strains, including A. muciniphila, and some actions on bile acids mediated by microbiota have been described. All these recent advances have been reported and discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits
De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., Bäckhed, F., & Mithieux, G. (2014) · Cell · doi:10.1016/j.cell.2013.12.016 · Cited by 2,200
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Human gut microbiome: Hopes, threats and promises
Cani, P. D. (2018) · Gut · doi:10.1136/gutjnl-2018-316723 · Cited by 1,386
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
The human microbiome: Our second genome
Grice, E. A., & Segre, J. A. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163814 · Cited by 759
Ding, S., Chi, M. M., Scull, B. P., Rigby, R., Schwerbrock, N. M. J., Magness, S., Jobin, C., & Lund, P. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012191 · Cited by 713
Cited by
Human gut microbiota in health and disease: Unveiling the relationship
Afzaal, M., Saeed, F., Shah, Y. A., Hussain, M., Rabail, R., Socol, C. T., Hassoun, A., Pateiro, M., Lorenzo, J. M., Rusu, A. V., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.999001 · Cited by 762
Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition
Rinninella, E., Cintoni, M., Raoul, P., Lopetuso, L. R., Scaldaferri, F., Pulcini, G., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019) · Nutrients · doi:10.3390/nu11102393 · Cited by 673
Xu, Y., Wang, N., Tan, H.-Y., Li, S., Zhang, C., & Feng, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00219 · Cited by 420
“muciniphila, lowgrade inflammation, and gut permeability disruption (Pascale et al., 2019).”
BackgroundThe Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation
Rahman, M. M., Islam, F., -Or-Rashid, M. H., Mamun, A. A., Rahaman, M. S., Islam, M. M., Meem, A. F. K., Sutradhar, P. R., Mitra, S., Mimi, A. A., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.903570 · Cited by 253
The influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 242
Targeting the Microbiota in Pharmacology of Psychiatric Disorders
Pascale, A., Marchesi, N., Govoni, S., & Barbieri, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104856 · Cited by 67
Self-citationMa, X., Xiao, W., Li, H., Pang, P., Xue, F., Wan, L., Pei, L., & Yan, H. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.02.011 · Cited by 67
Therapeutic Potentials of Microalgae and Their Bioactive Compounds on Diabetes Mellitus
Tamel Selvan, K., Goon, J. A., Makpol, S., & Tan, J. K. (2023) · Marine Drugs · doi:10.3390/md21090462 · Cited by 32
Metadata
- Authors
- Pascale, A., Marchesi, N., Govoni, S., Coppola, A., & Gazzaruso, C.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 49
- Pages
- 1-5
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2947087777
- Cited by
- 240
- References
- 20
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.